Curing APL: differentiation or destruction?

Cancer cell ·Vol. 15 ·No. 1 ·2009-01-06 ·页码 7-8

Kogan SC

Abstract

In a recent issue of Nature Medicine, Nasr et al. show that the effectiveness of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia is independent of their ability to cause differentiation. Targeted destruction of the PML-RARalpha oncoprotein appears key to eliminating the cells from which relapse can arise.

MeSH 主题词

Animals Antineoplastic Combined Chemotherapy Protocols/pharmacology,therapeutic use Arsenic Trioxide Arsenicals/pharmacology,therapeutic use Cell Differentiation/drug effects Humans Leukemia, Promyelocytic, Acute/drug therapy,pathology Oncogene Proteins, Fusion/metabolism Oxides/pharmacology,therapeutic use Tretinoin/pharmacology,therapeutic use

化学物质

Arsenicals Oncogene Proteins, Fusion Oxides promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein Tretinoin Arsenic Trioxide

作者与单位

共 1 位作者，点击展开单位 / ORCID

Kogan Scott C

Department of Laboratory Medicine and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA. [email protected]

Article Info

Journal

Cancer cell

Abbr.

Cancer Cell

ISSN

1878-3686

DOI

10.1016/j.ccr.2008.12.012

Corresponding email

[email protected]

Published

2009-01-06

页码

7-8

Language

English

Country/Region

United States

NLM ID

101130617

勘误 / 撤稿关联

CommentOn

PMID: 19029980

External Links

PubMed source DOI: 10.1016/j.ccr.2008.12.012 View journal details

Analysis Services

Curing APL: differentiation or destruction?

Contact

WeChat Official Account